Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicentre, Open-label, Nonrandomised, First-in-human Study of OVM-200 as a Therapeutic Vaccine in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Ovarian Cancer, and Prostate Cancer

NCT05104515 is registered in ClinicalTrials.gov with Oxford Vacmedix UK Ltd. as lead sponsor.

NCT NCT05104515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05104515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicentre, Open-label, Nonrandomised, First-in-human Study of OVM-200 as a Therapeutic Vaccine in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Ovarian Cancer, and Prostate Cancer
Lead sponsor
Oxford Vacmedix UK Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
November 1, 2021
Completion date
January 31, 2026
Enrollment
36 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer, ovarian cancer, prostate cancer